Status:
NOT_YET_RECRUITING
Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
Lead Sponsor:
Sorrento Therapeutics, Inc.
Conditions:
Cancer
Cancer of Pancreas
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a Phase 1b study to assess the safety and tolerability of STI-1386, an oncolytic virus, in subjects with relapsed and refractory solid tumors (RRSTs).
Detailed Description
This is a Phase 1b, dose-ascending study to assess the safety, tolerability and recommended phase 2 dose (RP2D) of STI-1386 in subjects with relapsed and refractory solid tumors (RRSTs). STI-1386 is a...
Eligibility Criteria
Inclusion
- Histologically confirmed extracranial solid tumors that are relapsing or refractory including locally advanced pancreatic cancer, unresectable soft tissue sarcomas, hepatic metastases due to colorectal cancer
- At least one measurable disease per Response Evaluation Criteria in Solid Tumors v. 1.1 (RECIST 1.1) with a non-nodal lesion with longest diameter ≥ 10 mm or nodal lesions with short diameter ≥ 15 mm
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
- As assessed by the investigator, ≥ 3 month life expectancy
- Adequate hematologic, liver and renal function at Screening as determined by lab criteria
- Recovered \< Grade 2 from all acute toxicities from previous therapy
- Has not had prior treatment with high dose corticosteroids within the 2 weeks of screening
- Is willing and able to comply with the study schedule and other protocol requirements
- Willing to follow contraception guidelines
Exclusion
- Have a primary brain tumor
- Use of an investigational drug or local therapy or agent within 2 weeks of first dose of study drug. Current systemic chemotherapy per investigator's discretion is allowed, but no immune checkpoint inhibitors or immune modulators
- Use of anticoagulants or anti-platelet agents unless subject can safely start/stop to allow intratumoral injections
- Use of bevacizumab (Avastin) within 28 days of the STI-1386 injection
- Diagnosis of other malignancies that have required therapy in the last year or are not in complete remission. Exceptions include non-metastatic basal cell or squamous cell carcinomas of the skin, prostate cancer or cancer in situ that does not require treatment currently or is otherwise under control
- Requiring chronic systemic immunosuppressants, including steroids \> 20 mg/day
- Presence of bulky disease defined as any single mass \> 5 cm in greatest dimension will trigger a discussion to determine eligibility
- New York Heart Association (NYHA) Class \>3 of left ventricular ejection fraction (LVEF) \< 50%
- Prolonged corrected QT interval as determined by 12-lead electrocardiogram
- Has spinal cord compression or clinically unstable brain metastases within 4 weeks of first dose of study drug
- Evidence of active herpes infection and/or chronic herpes infection requiring prophylactic antiviral medication that may not be discontinued
- Has an active or recent COVID-19 infection, must have a negative RT-PCR test and not have had symptoms within 4 weeks of day 1 of study drug administration
- Any active infection requiring systemic therapy within 72 hours of injection of STI-1386, excluding anti-viral maintenance therapy for HIV
- Moderate to severe chronic obstructive pulmonary disease or other moderate to severe chronic respiratory conditions unless under treatment and stable for the 3 months of screening
- Have active human immunodeficiency virus (HIV) infection, human T-cell leukemia virus type 1 (HTLV1) infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia
- Pregnant or lactating or up to 3 months post last dose
- Underlying medical conditions that, in the opinion of the investigator and/or medical monitor will prevent the subject from participating
- Allergy to acyclovir and related anti-HSV antiviral agents
Key Trial Info
Start Date :
August 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2027
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05361954
Start Date
August 1 2023
End Date
February 1 2027
Last Update
April 12 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.